Viewing Study NCT02418884



Ignite Creation Date: 2024-05-06 @ 3:57 AM
Last Modification Date: 2024-10-26 @ 11:41 AM
Study NCT ID: NCT02418884
Status: UNKNOWN
Last Update Posted: 2015-04-16
First Post: 2015-03-30

Brief Title: The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in CAD Patients With Diabetes Mellitus
Sponsor: Sir Run Run Shaw Hospital
Organization: Sir Run Run Shaw Hospital

Study Overview

Official Title: The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in CAD Patients With Diabetes Mellitus
Status: UNKNOWN
Status Verified Date: 2015-04
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study is designed to validate the hypothesis that the treatment of rosuvastatin could increase the score of Calcification of Coronary arteryCAC density in coronary artery diseaseCAD patients with diabetes mellitusCAD patients with diabetes who confirmed CAC will receive rosuvastatin 20mgd therapy for 24 months
Detailed Description: Calcification of atherosclerotic plaque is a complicated and organic active process which is one of the main pathologic features of atherosclerosis Widely coverage of CAC is correlated with the greater likelihood of coronary eventsWith the increasing density of CAC the risk of cardiovascular disease CVD declinesSome studies showed that the calcified plaque in stable CHD is denser

Statins are widely used in the treatment of atherosclerotic cardiovascular disease Treatment of statins may increase the density score of CAC thus promote the unstable atherosclerotic plaque to the stable plaque

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None